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Abstract: Background: Human lactate dehydrogenase 5 (hLDH5) represents a promising anticancer target, 
particularly for the treatment of hypoxic tumors, where it is often hyperexpressed. In fact, by catalyzing the 
reduction of pyruvate to lactate, hLDH5 allows the survival of tumor cells under hypoxic conditions by means of 
glycolysis. Despite the efforts dedicated to the identification and development of hLDH5 inhibitors, only few compounds 
showing promising activity in cancer cell lines have been reported. 
Objective: In the present study, we developed a virtual screening (VS) protocol aimed at identifying new small molecule 
inhibitors of hLDH5. 
Method: The VS strategy consisted in a pharmacophore-driven consenus docking (CD) approach, combining a structure-
based pharmacophore screening and CD protocol employing three different docking methods. 
Results: The VS protocol was applied to filter the Enamine commercial database and allowed the selection of three 
candidate ligands to be subjected to hLDH5 inhibition assays. One of the selected compounds showed a promising 
activity, compared to its low molecular weight, with an IC50 of 180.7 ± 16.5 μM. 
Conclusion: We identified a new small-molecule inhibitor of hLDH5 that can be considered as a new lead for the 
development of potent hLDH5 inhibitors. Moreover, these results demonstrate the reliability of the VS protocol 
developed. 
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1. INTRODUCTION 
 Human lactate dehydrogenase (hLDH) is the enzyme 
responsible for the catalysis of the last step of glycolysis, 
which is the reversible reduction of pyruvate to lactate, with 
simultaneous oxidation of cofactor NADH to NAD+. Five 
functional tetrameric human isoforms (hLDH1-5) are 
distinguished on the basis of the possible combinations of 
the two monomeric subunits: LDH-A and LDH-B. Among 
them hLDH5 (hLDH-A4) has attracted great attention 
initially as an anti-malarial target and, more recently, as a 
potential anticancer target, since it plays a key role in the 
metabolism of invasive tumours.[1] The hLDH5-catalyzed 
reduction of pyruvate to lactate allows a continued ATP 
production even under hypoxic conditions by means of 
glycolysis without the oxygen-dependent oxidative 
phosphorylation. hLDH5 is over-expressed in many human 
tumor tissues and it was found to correlate with tumor size 
and poor prognosis. Silencing this enzyme by genetic 
techniques or by pharmacological inhibition proved to 
decrease cell proliferation and migration.[2] Therefore, 
inhibition of hLDH5 may be considered as a challenging and 
promising anticancer strategy, since it should cause a 
starvation of cancer cells by reducing their conversion of 
glucose to lactate.[3,4] hLDH5 inhibition for the treatment of 
tumours is a potentially safe strategy, considering that 
individuals homozygous for LDH-A deficiency do not show 
any particular clinical symptoms except for myoglobinuria 
upon intense physical exertion.[5] In the last years, great 
efforts have been dedicated to the development of new 
hLDH5 inhibitors by both academic and industrial groups. A 
diacid malonate-based bifunctional inhibitor (compound 1 or 
AZ-33, Fig. 1) was developed by NMR fragment-based 
approaches at AstraZeneca UK. AZ-33 is very potent on the 
isolated enzyme (IC50 = 0.5 µM), but unfortunately it failed 
to reach a good activity on cancer cells, probably because of 
the diacid functionality that hinders membrane 
permeability.[6] Screening of the Genentech/Roche 
corporate compound collection and subsequent lead 
optimization led to the development of other hLDH5 
inhibitors, such as 2-thio-6-oxo-1,6-dihydropyrimidine 2 
(Fig. 1), which showed an inhibition potency in the low 
micromolar range (IC50 = 0.48 µM), but it was scarcely 
effective in reducing lactate production in cancer cells.[7] 
The most recent inhibitor discovered by Genentech Inc. is 
the trisubstituted hydroxylactam 3 (Fig. 1), which displayed 
a nanomolar affinity for the enzyme (IC50 = 3 nM), and it 
also reached an excellent potency in the reduction of lactate  
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Fig. (1). Structures of some hLDH5 inhibitors. 
 
production in pancreatic MiaPaca2 cancer cell line (IC50 = 
670 nM), showing very promising pharmacokinetic 
properties to be orally administered in mice.[8] Our group 
discovered a new class of N-hydroxyindole-based inhibitors 
of hLDH5, and one of the most active compound is reported 
in Fig. 1 (compound 4),[9-13] which inhibits the enzyme 
with IC50 values in the low micromolar range, and reduces 
lactate production and cell viability in various cancer cell 
cultures. As a further step in the development of this class, 
we functionalized N-hydroxyindole-based compounds with 
sugar portions in order to enhance their uptake by cancer 
cells, thus exploiting a dual targeting of the Warburg 
effect.[14] Among other chemical classes of LDH-inhibitors, 
N-acylhydrazone derivative 5 (Fig. 1), developed at the 
University of Bologna, inhibits hLDH5 at the micromolar 
level and reduces lactate production, NAD+/NADH ratio and 
induces apoptosis in cancer cells.[15] In the last few years, a 
certain number of new hLDH inhibitors, such as galloflavin, 
have been identified through receptor-based virtual screening 
(VS) studies [16] relying on docking into different crystal 
structures of the enzyme.[15,17] Recently, we developed and 
optimized a consensus docking (CD) protocol combining ten 
different docking methods, which was found to predict 
ligand binding poses better than the single docking 
procedures and showed to be a promising strategy for 
improving performance and hit rates of VS 
campaigns.[18,19] Our CD protocol has already been 
successfully employed for the identification of new non-
covalent fatty acid amide hydrolase (FAAH) inhibitors,[20] 
while a mixed ensemble/CD approach using only four 
docking procedures allowed the identification of mild hLDH 
inhibitors.[21] On the other hand, we recently demonstrated 
that receptor-based pharmacophore screening may represent 
a reliable strategy to identify new small molecule inhibitors 
of hLDH.[22] For this reason, we decided to develop a 
pharmacophore-driven CD approach combining 
pharmacophore-based VS and a CD protocol employing a 
reduced number of docking procedures, in order to identify 
novel compounds endowed with hLDH-A inhibitory activity 
(Fig. 2). 
2. MATERIALS AND METHODS 
2.1 Receptor-Based Pharmacophore Generation. The 
receptor-based pharmacophore hypothesis was developed 
based on the X-ray structure of human lactate dehydrogenase 
A (hLDH-A) in complex with the 2-amino-5-aryl-pyrazine 
inhibitor (compound 18) reported by Fauber et al. and the 
coenzyme NADH (PDB code 4M49).[23] The receptor-
based pharmacophore model was built by using the software 
PHASE.[24] After generating an exhaustive model including 
all the possible pharmacophore features identified by the 
software for compound 18, only the five features 
representing the main ligand-protein and ligand-cofactor 
interactions observed in the crystal structure were selected 
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and retained in the final pharmacophore model. The other 
features were thus discarded. The create_xvolReceptor utility 
of PHASE was used to generate the receptor excluded 
volume, representing the region of space surrounding the 
pharmacophore model that cannot be occupied by the 
database compounds when aligned to the model in a 
pharmacophore screening. The spheres defining the excluded 
volume shell were generated taking into account all the 
receptor and coenzyme heavy atoms placed at a distance 
ranging from 2 to 5 Å from the ligand surface. An additional 
excluded volume sphere representing the structural water 
molecule interacting with the ligand, R169 and the 
coenzyme was also considered. All other settings were left as 
their default. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Workflow of the pharmacophore-driven CD 
approach. 
2.2 Database Generation and Pharmacophore Screening. 
The Enamine database, including more than 1’700’000 
commercial compounds, was used as the screening database. 
The database was processed through the phasedb_manage 
and phasedb_confsites utilities of PHASE, in order to 
generate a PHASE 3D database in which multiple 
conformers, together with their corresponding 
pharmacophore sites, were created and stored for each 
molecule. The “thorough” sampling method was chosen, 
thus generating complete conformational ensembles for both 
the core and the peripheral groups of the compounds, while 
all other settings where left as their defaults. The PHASE 3D 
database was screened by using the pharmacophore model 
and the corresponding excluded volume previously 
generated. The pharmacophore search was carried out by 
setting the negative ionizable feature of the model as 
mandatory and the other ones as optional. Then, it was 
imposed that only the compounds matching at least three out 
of the five total features of the model and respecting the 
volume constraints were retrieved. 
2.3 Docking Procedures. The screened compounds were 
docked into the crystal structure of hLDH-A in complex with 
compound 18 and NADH (PDB code 4M49).[23] The 
coenzyme and the water molecule interacting with R169, the 
ligand and NADH was kept within the receptor pocket used 
for all the different docking calculations. Only the top-scored 
poses of the docked compounds were considered as a result 
of each docking procedure. 
GOLD 5.1. The docking site was defined as the region of 
space including all residues which stayed within 10 Å from 
the bound ligand in the hLDH-A X-ray structure. The 
compounds were subjected to 30 genetic algorithm runs 
employing ChemPLP as fitness function. The “allow early 
termination” option was disabled, while the possibility for 
the ligand to flip ring corners was enabled. The GOLD 
defaults were left for all other settings.[25] 
GLIDE 5.0. The docking grid was defined considering the 
bound ligand as the center of a cubic box of 10 Å in the x, y 
and z directions. The option allowing only the docking of 
ligands containing a defined range of atoms was disabled, so 
that all the ligands were docked independently from their 
number of atoms. The standard precision (SP) method was 
used for the study and all other settings were left as GLIDE 
defaults.[26] 
AUTODOCK 4.2.3. Receptor and ligands were processed by 
using AUTODOCK Tools to define the torsion angles in the 
compounds, to add the solvent model and to assign partial 
atomic charges to the ligands and the protein. The receptor 
site in which the compounds were docked was delimited by a 
grid box of 10 Å in the x, y and z directions centered on the 
bound ligand. Energetic map calculations were carried out by 
employing a grid spacing of 0.375 Å and a distance 
dependent function of the dielectric constant. Each docked 
compound was subjected to 20 Lamarckian genetic 
algorithm runs using 2’500’000 steps of energy evaluation 
and default values for all other parameters.[27] 
2.4 Pharmacophore-Driven Pose Filtering. Applying the 
three docking methods, three different binding dispositions 
were obtained for each compound docked into the hLDH-A 
binding site; these docking results were filtered through a 
rigid PHASE pharmacophore search, carried out by using the 
“ScoreInPlace” option. By applying this procedure, the top-
scored poses of the docked compounds were superimposed 
to the pharmacophore model without applying any change to 
their coordinates, and only the poses matching at least three 
out of the five total features of the model and respecting the 
volume constraints were retrieved. As in the pharmacophore 
screening, the matching of the negative ionizable feature was 
set as mandatory for pose retrieval. Only the compounds for 
which all three docking poses passed the filter were taken 
into account for the consensus docking analysis, while the 
other ones were discarded. 
2.5 Consensus Docking Evaluation. The RMSD of each of 
the three docking poses obtained for each compound against 
the remaining two was calculated by using the rms_analysis 
software of the GOLD suite.[28] On this basis, a 3x3 matrix 
was generated for each analyzed compound reporting the 
RMSD results. By using an in-house program these results 
were processed, so that the similar docking poses among the 
three results were clustered together. The complete-linkage 
method was used as clustering algorithm, which is an 
agglomerative type of hierarchical clustering. This method 
starts considering each element in a cluster of its own. The 
clusters are then sequentially combined into larger ones, 
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until all elements are in the same cluster. At each step, the 
two clusters separated by the shortest distance are combined. 
We selected an RMSD threshold of 1.5 Å, therefore the so 
obtained clusters contained the group of poses which were 
less than 1.5 Å away from all others poses belonging to the 
same cluster. 
2.6 Molecular Dynamic Simulations. All simulations were 
performed using AMBER 14.[29] The crystal structure of 
hLDH-A in complex with compound 18 and cofactor NADH 
(PDB code 4M49) was used as a template to set up the 
simulations protocol. The complexes were placed in a 
parallelepiped water-box (TIP3P explicit solvent model) and 
solvated with a 10 Å water cap; the system was then 
neutralized through the addition of chloride ions. General 
amber force field (GAFF) parameters were assigned to the 
ligands and NADH, while the AM1-BCC method was used 
to calculate their partial charges. Two different minimization 
steps were performed prior to the molecular dynamic (MD) 
simulations. The first step was carried out for the 
minimization of the solvent, by applying a position restraint 
of 100 kcal/(mol•Å2) to the complex. In the second step, only 
the protein α carbons were restrained with a harmonic 
potential of 10 kcal/(mol•Å2), thus the whole system was 
minimized through 10’000 steps of steepest descent followed 
by conjugate gradient, until a convergence of 0.05 
kcal/(mol•Å2) was reached. The minimized complexes were 
used as input structures for the MD simulations which were 
run by using particle mesh Ewald electrostatics, a cutoff of 
10 Å for the non-bonded interactions and periodic boundary 
conditions. SHAKE algorithm was employed to keep all 
bonds involving hydrogen fixed, thus a simulation time step 
of 2.0 fs was used. Constant-volume periodic boundary 
conditions were used for the first 300 ps of simulation, 
during which the temperature was raised from 0 to 300 K. 
Constant-pressure conditions were employed for the 
remaining 4.7 ns of MD simulation, while the system 
temperature was kept constant at 300 K by using the 
Langevin thermostat. A total of 5 ns of MD simulation was 
thus performed for each ligand-protein-cofactor complex 
studied. The analysis of the MD trajectories to calculate H-
bonds and water-bridged interactions occupancies, as well as 
the RMSD of the ligands with respect to their input poses, 
were performed by using the Cpptraj suite of AMBER 14. 
2.7 Enzymatic Essays. The inhibition properties of the 
compounds were evaluated against purified human lactate 
dehydrogenase isoform 5 (Lee Biosolution, Inc.). The 
“forward” direction (pyruvate → lactate) of the lactate 
dehydrogenase reaction was conducted, and the kinetic 
parameters were measured by fluorescence (emission 
wavelength at 460 nm, excitation wavelength at 340 nm) to 
monitor the rate of conversion of NADH to NAD+. 
Compounds were tested in the presence of scalar 
concentrations of NADH. They were added in scalar 
amounts (concentration range = 10–200 μM) to a reaction 
mixture containing phosphate buffer, 1.4 mM pyruvate and 
scalar concentrations of NADH (12.5 µM-150 µM). Finally, 
LDH solution was added (0.015 U•mL-1). The LDH activity 
was measured by recording the decrease in NADH 
fluorescence using a Victor X3 Microplates Reader 
(PerkinElmer®). The experimental data were analyzed by 
non-linear regression analysis with GraphPad Prism 
software, using a second order polynomial regression 
analysis, and by applying the mixed-model inhibition fit.[30] 
3. RESULTS AND DISCUSSION. 
With the aim of identifying small molecule inhibitors of 
hLDH5 belonging to novel chemical classes, we developed a 
pharmacophore-driven consensus docking (CD) strategy 
combining a receptor-based pharmacophore search with a 
consensus docking approach. The pharmacophore model was 
derived from the X-ray structure of hLDH-A complexed 
with the cofactor NADH and the 2-amino-5-aryl-pyrazine 
inhibitor compound 18 reported by Fauber et al. (PDB code 
4M49).[23] As shown in Fig. 3, this inhibitor is anchored to 
the active site of the enzyme thanks to a series of hydrogen 
bonds established with both protein residues and NADH. 
The carboxylic group of the ligand shows ionic interactions 
with the positively charged H193, which is a key residue for 
the enzyme catalytic activity, while four different hydrogen 
bonds are formed by its 2-aminopyrazine moiety: one with 
the backbone oxygen of T248, another one with the hydroxyl 
group of the same residue and two different H-bonds with a 
pyrophosphate oxygen of NADH. Moreover, a structural 
water molecule is supposed to mediate an H-bond network 
among the ligand carboxylic group, the amide carbonyl of 
the cofactor and the guanidine group of R169, which is 
another fundamental catalytic residue of the enzyme. In fact, 
these water bridged interactions (Fig. 3) are clearly shown in 
chain A of the crystal structure 4M49. In the other two 
chains were the ligand is bound to the enzyme (chains C and 
D), such a water molecule is either absent or 4.6 Å away 
from the inhibitor carboxylic group, being involved in a 
different water bridged H-bond between R169 and T248. In 
chain B, the inhibitor is replaced by a lactate molecule, 
which is the substrate of the enzyme. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Main ligand-protein interactions identified in the X-
ray structure of hLDH, chain A, in complex with compound 
18 (stick) and NADH. Hydrogen bonds are shown as black 
dashed lines. 
In order to estimate the importance of these possible water 
mediated H-bonds and the strength of the direct interactions 
between ligand and protein/cofactor, we performed a 5 ns 
long MD simulation and analyzed the stability of the whole 
complex. After only 400 ps of MD simulation the system 
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reached an equilibrium, since during the following 4.6 ns of 
simulation its total energy was found to be constant, while 
the protein heavy atoms showed an average root-mean-
square deviation (RMSD) with respect to the input structure 
of 1.0 Å (Fig. S1 in Supporting Information). The ligand and 
the coenzyme NADH perfectly maintained their binding 
disposition within the protein catalytic site, since their 
average RMSD with respect to the corresponding 
crystallographic pose were found to be 0.96 and 0.75 Å, 
respectively. Moreover, all the interactions identified in the 
X-ray complex were maintained for most of the MD 
simulation. In particular, the ligand H-bonds with H193, 
T248 and NADH showed more than 95% of occupancy, 
while the water-bridged interaction among R169, the ligand 
and the cofactor was detected for about 70% of the whole 
simulation. Given the results obtained with the MD 
simulation analysis, we decided to build a receptor-based 
pharmacophore model taking into account all the ligand 
moieties involved in these interactions to be used in a VS 
study. Therefore, the generated pharmacophore model (Fig. 
4) included a negative ionizable feature representing the 
inhibitor carboxylic group interacting with H193 and the 
structural water molecule, an H-bond acceptor feature 
representing its aromatic nitrogen interacting with T248 
hydroxyl group and three H-bond donor features 
representing the three NH groups of the ligand interacting 
with NADH and T248 backbone oxygen. The 
pharmacophore model was completed with an excluded 
volume shell composed by spheres mimicking the steric 
hindrance of the receptor, which were generated by taking 
into account the heavy atoms of the cofactor and protein 
residues in proximity of the ligand, as well as the structural 
water molecule. 
 
 
 
 
 
 
 
 
 
Fig. (4). Receptor-based pharmacophore model used for the 
VS study; the reference inhibitor together with the negative 
(dark gray), H-bond acceptor (gray) and H-bond donor (pale 
gray) features are shown; the excluded volume spheres are 
hidden for clarity. 
The receptor-based pharmacophore model was used to 
screen the Enamine database, collecting about 1’700’000 
commercially available compounds. Since the carboxylic 
group of compound 18 was responsible of the interactions 
with the catalytic residues H193 and R169, the 
pharmacophore screening was performed by setting the 
negative ionizable feature of the model as obligatory, while 
the other features were set as optional. The compounds 
matching at least three out of the five pharmacophore 
features of the model and satisfying the steric constraints of 
the receptor were retrieved during the screening. By applying 
this filter, only 8759 compounds were selected and taken 
into account for docking studies. As mentioned above, we 
have recently developed a CD protocol combining different 
docking procedures, whose reliability in VS studies has been 
extensively tested using enriched databases and 
experimentally confirmed through the identification of new 
FAAH and LDH inhibitors. In the present VS study we 
decided to use a pharmacophore-driven CD protocol, i.e. a 
simplified CD approach employing three docking methods to 
identify only those compounds that were most likely to bind 
LDH catalytic site by assuming a disposition fitting the 
receptor-based pharmacophore. The 8759 compounds 
selected through the pharmacophore screening were thus 
docked into the crystal structure of hLDH-A in presence of 
NADH and the structural water molecule (PDB code 4M49), 
by using three procedures whose reliability in docking LDH 
inhibitors was previously assessed through enriched database 
analysis (i.e. Autodock, GLIDE with the SP method and 
GOLD with ChemPLP fitness function).[21] Then, before 
performing pose clustering, we first superimposed each 
docking result to the receptor-based pharmacophore model. 
Only the compounds for which all the three docking poses 
(obtained using the three different procedures) matched at 
least three out of the five features of the model were 
considered for the CD analysis. Moreover, the matching of 
the negative ionizable feature was set as mandatory in this 
post-docking filter, as imposed in the pharmacophore 
screening. As a result, only 316 compounds were retained 
and subjected to pose clustering, in order to search for 
common binding modes. In our latest evaluation and 
optimization of the CD procedure with enriched databases, 
we studied the effect of the RMSD tolerance used for pose 
clustering on the VS performance and we evidenced that the 
best results in terms of enrichment factors were obtained by 
using an RMSD cutoff of 1.5 Å. For this reason, we used the 
same RMSD threshold for the CD analysis of the 316 
compounds passing the pharmacophore-driven pose filter. 
As shown in Table 1, only 15 compounds reached a 
consensus level of 3, which was also obtained for the 
reference inhibitor, compound 18. 
Table 1. Consensus docking results for the filtered 
commercial compounds. 
Consensus Level Number of Compounds 
3 15 
2 85 
1 216 
 
These ligands were thus subjected to MD simulation studies 
to verify the stability of their predicted binding mode by 
using the same MD protocol reported above that was tested 
on the reference X-ray complex. The RMSD of the position 
of each ligand during the whole 5 ns of simulation, with 
respect to the corresponding docking pose, was calculated 
and the 6 compounds showing an average RMSD higher 
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than 1.5 Å were discarded. The remaining 9 ligands were 
further analyzed to evaluate the stability of their interactions 
with the cofactor and the protein residues represented in the 
receptor-based pharmacophore model. The three compounds 
maintaining the interaction with H193 for more than 90% of 
the whole simulation and at least two other interactions with 
NADH, T248 and R169 (considering the water-bridged H-
bond), for at least 70% of the simulation were selected to be 
purchased and tested for their inhibitory activity against 
hLDH5. Table 2 reports the biological results obtained for 
the selected ligands, together with the known inhibitor 
galloflavin that was used as a reference: compound VS3 
showed a promising activity, with an IC50 of 180.7 ± 16.5 
μM. In fact, due to its very low molecular weight and 
number of heavy atoms, compound VS3 demonstrated a 
higher ligand-efficiency (LE = 0.40)[31] compared to that 
calculated for compound 18 (LE = 0.31) and galloflavin (LE 
= 0.28), although showing a lower activity (compound 18 
IC50 = 2 μM). [23] Hence, compound VS3 could represent a 
valuable starting point for a lead optimization campaign. 
Table 2. Structure and hLDH5 inhibitory activity of the 
tested compounds. 
 Structure IC50 (μM) 
VS1 
 
>>500 
VS2 
 
494.1 ± 
42.2 
VS3 
 
180.7 ± 
16.5 
Galloflavin 
 
91.7 ± 10.7 
 
Fig. 5 shows the predicted binding mode of compound VS3. 
The ligand is placed with its bicyclic core between A238 and 
I242 from one side, and NADH from the other side, thus 
forming van der Waals interactions with both these residues 
and the cofactor. The amino group of the ligand forms two 
different hydrogen bonds that were maintained for more than 
80% of the MD simulation: one with the backbone oxygen of 
T248 and another one with NADH pyrophosphate. The 
carboxylic group of compound VS3 is placed in close 
proximity of both the catalytic residue H193, with which it 
interacts during the whole MD simulation, and the structural 
water molecule; in fact, the water bridged H-bond network 
involving the ligand, NADH and R169 was detected for 
more than 90% of the simulation. Finally, a hydroxyl group 
of NADH forms an additional hydrogen bond with the ligand 
endocyclic oxygen. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Minimized average structure of compound VS3 
docked into hLDH-A catalytic site. 
4. CONCLUSIONS. 
In the present study, we developed a pharmacophore-driven 
CD protocol focused on the identification of new hLDH5 
inhibitors. For this purpose, we built a receptor-based 
pharmacophore model based on the X-ray structure of 
hLDH-A in complex with the cofactor NADH and a 2-
amino-5-aryl-pyrazine inhibitor. The generated 
pharmacophore model, representing the key ligand-protein 
and ligand-cofactor interactions identified in the 
crystallographic complex, was used to filter a database 
including about 1’700’000 compounds. The ligands selected 
through the screening were subjected to a CD approach 
employing three docking methods and aimed at identifying 
the compounds that were most likely to bind LDH catalytic 
site assuming a disposition fitting the pharmacophore model. 
The predicted binding mode of the top-scored compounds 
was then analyzed through MD simulations studies, which 
allowed the selection of three candidate ligands that were 
tested for hLDH5 inhibitory activity. Enzymatic assays 
revealed a promising activity for one of the selected 
compound, which showed an IC50 of 180.7 ± 16.5 μM, and 
thus validated the reliability of the VS protocol herein 
described. Moreover, the identified ligand can already be 
considered as a new lead compound for the development of 
potent hLDH5 inhibitors, especially considering its simple 
chemical scaffold and very low molecular weight (compared 
to the reference inhibitors galloflavin and compound 18), 
which can allow a wide range of possible ligand 
functionalization in future lead optimization studies. A series 
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of derivatives of compound VS3 will be thus synthesized in 
order to develop more potent analogues, and with the aim of 
identifying highly active ligands to be subjected to cell 
proliferation and migration assays. 
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